問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Otolaryngology

Division of General Internal Medicine

Division of Hematology & Oncology

Division of General Surgery

Division of Colorectal Surgery

Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

National Taiwan University Hospital

更新時間：2023-09-19

邱泰然Chiu, Tai-Jan
  • Principal Investigator
  • Clinical Trial Experience (year) 13 years 2 個月

  • kuerten@cgmh.org.tw

Recruiting Trial

116Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

邱泰然

List

220Cases

2018-08-18 - 2022-07-11

Phase III

FIGHT: A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 3 Preceded by Dose-Finding in Phase 1

  • Condition/Disease

    Untreated Advanced Gastric and Gastroesophageal Cancer

  • Test Drug

    FPA144

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting1Sites

Terminated4Sites

白禮源
China Medical University Hospital-Taipei

未分科

2007-07-02 - 2012-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2015-07-01 - 2026-05-29

Phase III

A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence

  • Condition/Disease

    Melanoma

  • Test Drug

    Nivolumab, Ipilimumab

Participate Sites
4Sites

Terminated3Sites

林振源
China Medical University Hospital-Taipei

未分科

林振源
China Medical University Hospital

Division of Hematology & Oncology

2022-06-01 - 2026-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2019-12-01 - 2022-12-31

Phase I

A Phase I Open-Label Study of the Safety and Tolerability of ATG-019, a Dual Inhibitor of PAK4 and NAMPT, in patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma.

  • Condition/Disease

    Solid Tumor/Non-Hodgkin's Lymphoma

  • Test Drug

    ATG-019

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2014-11-01 - 2019-03-31

Phase III

ONO-4538 Phase III Study A Multicenter, Double-Blind, Randomized Study in Patients with Unresectable Advanced or Recurrent Gastric Cancer

  • Condition/Disease

    Unresectable Advanced or Recurrent Gastric Cancer

  • Test Drug

    ONO-4538

Participate Sites
9Sites

Terminated9Sites

2014-04-01 - 2016-09-30

Phase III

Phase III Study of IV Vinflunine in Combination With Methotrexate Versus Methotrexate Alone in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-based Chemotherapy

  • Condition/Disease

    Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    Javlor

Participate Sites
7Sites

Terminated7Sites

2010-12-01 - 2020-12-07

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated6Sites

Suspended3Sites

2014-07-01 - 2021-11-30

Phase II

A Phase 2, Randomized, Double-blind Study of Gemcitabine and Nab-paclitaxel combined with Momelotinib in Subjects with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, Lead-in Phase

  • Condition/Disease

    Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

  • Test Drug

    Momelotinib

Participate Sites
7Sites

Terminated6Sites

2023-10-01 - 2030-12-31

Phase III

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)

  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    Rilvegostomig

Participate Sites
8Sites

Recruiting8Sites

1 18 19 20 21 22
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB